Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis

Journal of Thoracic and Cardiovascular Surgery

Volumn 145, Issue 5, 2013, Pages 1305-1311

  Baud, Mariette ^a,b   Strano, Salvatore ^c   Dechartres, Agnes ^c   Jouni, Rami ^c   Triponez, Frederic ^c   Chouaid, Christos ^b   Forgez, Patricia ^a   Damotte, Diane ^c   Roche, Nicolas ^c   Régnard, Jean François ^c   Alifano, Marco ^a,c  

^a CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; C REACTIVE PROTEIN; GEMCITABINE; PEMETREXED;

AGED; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PLEURODESIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; TOBACCO; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BIOPSY; C-REACTIVE PROTEIN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKOCYTOSIS; MALE; MESOTHELIOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLEURAL NEOPLASMS; PLEURODESIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THORACIC SURGERY, VIDEO-ASSISTED; TIME FACTORS; TREATMENT OUTCOME;

EID: 84876413713     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2012.09.023     Document Type: Article

References (28)

1. A. Marinaccio, A. Binazzi, D.D. Marzio, A. Scarselli, M. Verardo, and D. Mirabelli Pleural malignant mesothelioma epidemic: incidence, modalities of asbestos exposure and occupations involved from the Italian National Register Int J Cancer 130 2012 2146 2154
2. J.E. Craighead Epidemiology of mesothelioma and historical background Recent Results Cancer Res 189 2011 13 25
3. B. Price, and A. Ware Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005 Crit Rev Toxicol 39 2009 576 588
4. N.J. Olsen, P.J. Franklin, A. Reid, N.H. de Klerk, T.J. Threlfall, and K. Shilkin Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation Med J Austr 195 2011 271 274
5. C.T. Ducko, and D.J. Sugarbaker Pleural tumors J.D. Cooper, J. Deslauriers, A.E.M.R. Lerut, Pearsons's thoracic & esophageal surgery 3rd edition 2008 Churchill Livingstone Philadelphia 1121 1136
6. C.A. Moran, M.R. Wick, and S. Suster The role of immunohistochemistry in the diagnosis of malignant mesothelioma Semin Diagn Pathol 17 2000 178 183
7. A.N. Husain, T.V. Colby, N.G. Ordóñez, T. Krausz, A. Borczuk, and P.T. Cagle Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group Arch Pathol Lab Med 133 2009 1317 1331
8. N.J. Vogelzang, J.J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, and P. Ruffie Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma J Clin Oncol 21 2003 2636 2644
9. J.P. van Meerbeeck, R. Gaafar, C. Manegold, R.J. Van Klaveren, E.A. Van Marck, and M. Vincent Randomized phase III study of cisplatin with or without ralitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada J Clin Oncol 23 2005 6881 6889
10. T.R. Tilleman, W.G. Richards, L. Zellos, B.E. Johnson, M.T. Jaklitsch, and J. Mueller Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study J Thorac Cardiovasc Surg 138 2009 405 411
11. T.D. Yan, M. Boyer, M.M. Tin, D. Wong, C. Kennedy, and J. McLean Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors J Thorac Cardiovasc Surg 138 2009 619 624
12. P.H. Schipper, F.C. Nichols, K.M. Thomse, C. Deschamps, S.D. Cassivi, and M.S. Allen Malignant pleural mesothelioma: surgical management in 285 patients Ann Thorac Surg 85 2008 257 264
13. R.M. Flores, L.M. Krug, K.E. Rosenzweig, E. Venkatraman, A. Vincent, and R. Heelan Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial J Thorac Oncol 1 2006 289 295
14. F. Rea, G. Marulli, L. Bortolotti, C. Breda, A.G. Favaretto, and L. Loreggian Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results Lung Cancer 57 2007 89 95
15. A. Hasani, J.M. Alvarez, J.M. Wyatt, S. Bydder, M. Millward, and M. Byrne Outcome for patients with malignant pleural mesothelioma referred for trimodality therapy in western Australia J Thorac Oncol 4 2009 1010 1016
16. F. Montanaro, R. Rosato, M. Gangemi, S. Roberti, F. Ricceri, and E. Merler Survival of pleural malignant mesothelioma in Italy: a population-based study Int J Cancer 124 2009 201 207
17. D.J. Sugarbaker, R.M. Flores, M.T. Jaklitsch, W.G. Richards, G.M. Strauss, and J.M. Corson Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients J Thorac Cardiovasc Surg 117 1999 54 63
18. P.E. Van Schil, P. Baas, R. Gaafar, A.P. Maat, M. Van de Pol, and B. Hasan Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial Eur Respir J 36 2010 1362 1369
19. T. Treasure, L. Lang-Lazdunski, D. Waller, J.M. Bliss, C. Tan, and J. Entwisle Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study Lancet Oncol 12 2011 763 772
20. G. Lazennec, and A. Richmond Chemokines and chemokine receptors: new insights into cancer-related inflammation Trends Mol Med 16 2010 133 144
21. M.B. Pepys, and G.M. Hirschfield C-reactive protein: a critical update J Clin Invest 111 2003 1805 1812
22. A. Koch, H. Fohlin, and S. Sorenson Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy J Thorac Oncol 4 2009 326 332
23. M. Alifano, P.E. Falcoz, V. Seegers, N. Roche, O. Schussler, and M. Younes Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer J Thorac Cardiovasc Surg 142 2011 1161 1167
24. M. Hara, Y. Matsuzaki, T. Shimuzu, M. Tomita, T. Ayabe, and Y. Enomoto Preoperative serum C-reactive protein level in non-small cell lung cancer Anticancer Res 27 2007 3001 3004
25. D. Curran, T. Sahmoud, P. Therasse, M.J. Van, P.E. Postmus, and G. Giaccone Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience J Clin Oncol 16 1998 145 152
26. J.E. Herndon, M.R. Green, A.P. Chahinian, J.M. Corson, Y. Suzuki, and N.J. Vogelzang Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B Chest 113 1998 723 731
27. A.C. Tanrikulu, A. Abakay, M.A. Kaplan, M. Kucukoner, Y. Palanci, and O. Evliyaoglu A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma Respiration 80 2010 480 487
28. S.C. Kao, R. Harvie, F. Paturi, R. Taylor, R. Davey, and R. Abraham The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine Lung Cancer 75 2012 248 254